Published in Histopathology on May 24, 2010
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol (2012) 1.78
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) (2011) 1.45
Genome evolution during progression to breast cancer. Genome Res (2013) 1.37
Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.32
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) (2014) 1.13
Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Mod Pathol (2016) 1.05
Vitamin D and the mammary gland: a review on its role in normal development and breast cancer. Breast Cancer Res (2012) 1.02
Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care (Basel) (2011) 1.00
Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology. J Pathol Inform (2014) 0.97
Epigenetic regulation of estrogen signaling in breast cancer. Epigenetics (2013) 0.94
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clin Cancer Res (2014) 0.89
Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res (2012) 0.87
Roles of microRNA-140 in stem cell-associated early stage breast cancer. World J Stem Cells (2014) 0.87
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol (2014) 0.87
Ductal carcinoma in situ: what the pathologist needs to know and why. Int J Breast Cancer (2013) 0.86
Molecular drivers of lobular carcinoma in situ. Breast Cancer Res (2015) 0.86
Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. Breast Cancer Res Treat (2014) 0.83
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat (2013) 0.83
EZH2 expression in invasive lobular carcinoma of the breast. World J Surg Oncol (2013) 0.82
Absence of microsatellite instability in mucinous carcinomas of the breast. Int J Clin Exp Pathol (2010) 0.81
A comparison of the risks of in-breast recurrence after a diagnosis of dcis or early invasive breast cancer. Curr Oncol (2014) 0.81
Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast. J Histochem Cytochem (2015) 0.81
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells. Breast Cancer Res (2014) 0.81
Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Mol Oncol (2015) 0.80
Identification and functional annotation of genome-wide ER-regulated genes in breast cancer based on ChIP-Seq data. Comput Math Methods Med (2012) 0.80
Molecular classification of breast cancer. Virchows Arch (2014) 0.80
Significance of rat mammary tumors for human risk assessment. Toxicol Pathol (2014) 0.80
Application of imaging mass spectrometry for the molecular diagnosis of human breast tumors. Sci Rep (2016) 0.79
Copy number analysis of ductal carcinoma in situ with and without recurrence. Mod Pathol (2015) 0.79
Long-term culture of human breast cancer specimens and their analysis using optical projection tomography. J Vis Exp (2011) 0.79
Force-dependent breaching of the basement membrane. Matrix Biol (2016) 0.78
Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology. Microarrays (Basel) (2015) 0.77
Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions. J Cancer Res Clin Oncol (2014) 0.77
Prognostic value of molecular markers and cytogenetic alterations that characterize breast cancer precursor lesions (Review). Oncol Lett (2013) 0.77
Histopathologcial and clonal study of combined lobular and ductal carcinoma of the breast. Pathol Int (2013) 0.76
Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer. Int J Clin Exp Pathol (2015) 0.75
[Breast cancer in Morocco: phenotypic profile of tumors]. Pan Afr Med J (2016) 0.75
Noncoding RNAs in breast cancer. Brief Funct Genomics (2015) 0.75
Appraisal of progenitor markers in the context of molecular classification of breast cancers. Breast Cancer Res (2011) 0.75
Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysis. Onco Targets Ther (2015) 0.75
Bioanalytical LC-MS Method for the Quantification of Plasma Androgens and Androgen Glucuronides in Breast Cancer. J Chromatogr Sci (2016) 0.75
Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer. Microarrays (Basel) (2016) 0.75
Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. J Pathol (2016) 0.75
The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. Nat Commun (2017) 0.75
Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J Breast Health (2013) (2015) 0.75
Cancer stem cells and early stage basal-like breast cancer. World J Obstet Gynecol (2016) 0.75
Is the Outcome at Surgery Different When Flat Epithelial Atypia and Lobular Neoplasia are Found in Association at Biopsy? Br J Radiol (2017) 0.75
Can positron emission mammography help to identify clinically significant breast cancer in women with suspicious calcifications on mammography? Eur Radiol (2016) 0.75
Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Mod Pathol (2017) 0.75
Progressive polarity loss and luminal collapse disrupt tissue organization in carcinoma. Genes Dev (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Triple-negative breast cancer. N Engl J Med (2010) 11.39
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat (2009) 2.85
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
Molecular evolution of breast cancer. J Pathol (2005) 2.69
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Genetic interactions in cancer progression and treatment. Cell (2011) 2.54
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol (2007) 2.44
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res (2009) 2.42
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol (2010) 2.23
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol (2009) 2.17
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res (2007) 2.12
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol (2007) 2.09
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2008) 2.06
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol (2007) 2.00
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 1.99
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res (2009) 1.98
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Genetic heterogeneity and cancer drug resistance. Lancet Oncol (2012) 1.91
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. N Engl J Med (2010) 1.90
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat (2007) 1.84
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol (2010) 1.79
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol (2010) 1.79
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res (2007) 1.78
Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol (2008) 1.75
Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol (2010) 1.70
Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol (2005) 1.70
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol (2012) 1.67
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 1.64
Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol (2010) 1.63
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest (2006) 1.59
Histological types of breast cancer: how special are they? Mol Oncol (2010) 1.58
Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics (2005) 1.52
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat (2008) 1.51
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res (2009) 1.49
DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A (2010) 1.48
Non-existence of caveolin-1 gene mutations in human breast cancer. Breast Cancer Res Treat (2011) 1.47
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst (2011) 1.45
Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat (2010) 1.43
Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol (2004) 1.41
Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol (2008) 1.41
Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell phenotype. J Pathol (2004) 1.41
Tackling the diversity of triple-negative breast cancer. Clin Cancer Res (2013) 1.41
Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer (2010) 1.40
Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res (2004) 1.39
Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells (2012) 1.35
Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab Invest (2007) 1.35
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest (2008) 1.35
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res (2007) 1.33
Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One (2009) 1.33
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res (2011) 1.30
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2009) 1.29
Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res (2007) 1.29
FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res (2011) 1.29
Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res (2007) 1.28
Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol (2013) 1.28